The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial…
The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the…
A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells, suggesting that it could be…
The first patient-led crowdsourcing and crowdfunding initiative for multiple myeloma (MM) research has exceeded its goal of raising $500,000 to advance new…
Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies…
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…